2 years after rejection, Mesoblast touts long-term cell therapy survival data as key to FDA resubmission
https://www.fiercebiotech.com/biotech/2-years-after-rejection-mesoblast-touts-long-term-cell-therapy-survival-data-key-fda
Medical Innovation Exchange @ Copywrite 2021. All Rights Reserved.